# Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis

> **NCT06411314** · PHASE3 · COMPLETED · sponsor: **Avva Rus, JSC** · enrollment: 218 (actual)

## Conditions studied

- Vulvovaginal Candidiasis, Genital

## Interventions

- **COMBINATION_PRODUCT:** Natamycin + Lactulose 100 mg + 300 mg vaginal suppositories
- **DRUG:** Lactulose 300 mg vaginal suppositories
- **DRUG:** Pimafucin® (natamycin) 100 mg vaginal suppositories

## Key facts

- **NCT ID:** NCT06411314
- **Lead sponsor:** Avva Rus, JSC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-29
- **Primary completion:** 2023-07-26
- **Final completion:** 2023-09-22
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2024-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06411314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06411314, "Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06411314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*